

## **NEWS RELEASE**

## RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 22<sup>nd</sup> January 2024 — Within the Recordati's share buy-back program communicated to the market on 29<sup>th</sup> September 2023 and initiated on 2<sup>nd</sup> October 2023, as per authorization granted by the Shareholders' Meeting held on 21<sup>st</sup> April 2023, with the object of the servicing of current and future stock option / performance shares plans in favour of the Recordati Group's management or share-based incentive plans that might be approved by the Company in the future, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/EU, on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made from 15<sup>th</sup> to 19<sup>th</sup> January 2024 in Recordati ordinary shares (ISIN IT0003828271) are as follows:

SUMMARY OF PURCHASE TRANSACTIONS							
Date	Type of	Quantity	Weighted average price	Exchange			
	Transaction		(Euro)				
15/01/2024	Purchase	96	50.5813	MTA			
TOTAL		96	50.5813				

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 19<sup>th</sup> January 2024, the Company held no. 2,932,466 treasury shares which amount to 1.402% of the current share capital.

**Recordati** (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their life. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2022, Recordati employed more than 4,300 people and consolidated revenue of € 1,853.3 million. For more information, please visit www.recordati.com.

## RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Tel. +39 02 487871 Fax +39 02 40073747 www.recordati.com

Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832



## **NEWS RELEASE**

Attachment:

Daily details of transactions

Date	Time (GMT)	Currency	Exchange	Price	Quantity
15/01/2024	14:11:21	EUR	MTA	50,6000	23
15/01/2024	14:11:21	EUR	MTA	50,6000	25
15/01/2024	14:11:27	EUR	MTA	50,5600	12
15/01/2024	14:11:27	EUR	MTA	50,5800	21
15/01/2024	14:11:29	EUR	MTA	50,5400	15